- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Gasparetto on Results for Selinexor and Daratumumab in Relapsed/Refractory Multiple Myeloma
Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.
Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab.
Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.
Related Content:
